Zevra Therapeutics
ZVRA
70 hedge funds and large institutions have $404M invested in Zevra Therapeutics in 2022 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 17 increasing their positions, 22 reducing their positions, and 8 closing their positions.
866% more capital invested
Capital invested by funds: $41.8M → $404M (+$362M)
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
1% more funds holding
Funds holding: 69 → 70 (+1)
1% less call options, than puts
Call options by funds: $4.05M | Put options by funds: $4.11M
2.25% less ownership
Funds ownership: 19.41% → 17.16% (-2.2%)
23% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 22
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| 1 |
Citadel Advisors
Miami,
Florida
|
+$553K |
| 2 |
Group One Trading
Chicago,
Illinois
|
+$386K |
| 3 |
Citigroup
New York
|
+$344K |
| 4 |
Jane Street
New York
|
+$162K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$128K |
Top Sellers
| 1 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
-$2.13M |
| 2 |
BlackRock
New York
|
-$1.24M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$907K |
| 4 |
E
Ergoteles
New York
|
-$535K |
| 5 |
Millennium Management
New York
|
-$385K |
ZVRA Hedge Fund Activity: Q4 2022 in Review
70 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q4 2022, worth a combined $404M — up 866% from $41.8M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new ZVRA positions and 8 closed out — a net gain of 2 holders — while 17 added to existing stakes and 22 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $553K. The largest seller was HealthInvest Partners, cutting an estimated $2.13M.
- 70 institutional investors held Zevra Therapeutics (ZVRA) as of Q4 2022, up from 69 in Q3 2022.
- Funds reported $404M of Zevra Therapeutics stock for Q4 2022, up 866% quarter-over-quarter.
- 10 funds opened new Zevra Therapeutics positions in Q4 2022 and 8 closed out, a net change of +2 holders.
- The largest Zevra Therapeutics buyer in Q4 2022 was Citadel Advisors, an estimated $553K added.
- The largest Zevra Therapeutics seller in Q4 2022 was HealthInvest Partners, an estimated $2.13M sold.
Based on aggregated 13F filings for Q4 2022.